Etharums ser quidem rerum facilis dolores nemis omnis fugats vitaes nemo minima rerums unsers sadips amets.
BioMark has invested and successfully discovered and validated a new high-powered metabolic panel assay for early diagnosis of Lung Cancer. This performance panel assay has clinically demonstrated superior detection capabilities for early stage I / II Lung Cancers using urine and plasma. This is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a vintage position for high risk lung cancer screening market which currently uses low dose CT scans (LDCT). ML being incorporated in the analysis of the assay.
Application:
Clinical Trials:
Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open
Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute
Status: Open
Glioblastoma (GBM)
Breast Cancer
Head / Neck Cancer